Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis

Keat, A. C., Gaffney, K. ORCID:, Gilbert, A. K., Harris, C. and Leeder, J. (2008) Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology, 47 (4). pp. 481-483. ISSN 1462-0324

Full text not available from this repository. (Request a copy)


OBJECTIVE: To answer the question 'does TNF blockade therapy enable people with severe AS to return to work or work more productively?'. METHODS: All patients with AS currently receiving anti-TNF therapy at two UK Hospitals were asked to complete a questionnaire. This asked about occupational history, type of work, degree of job-related physical activity, working hours and sickness absence from work both currently (on anti-TNF treatment) and pre-treatment. RESULTS: Sixty-five patients (72.3% male), aged 29-64 (mean 46.1) yrs, whose duration of anti-TNF treatment ranged from 3 to 56 (mean 19.1) months were studied. Twenty-four (36.9%) patients were receiving infliximab, 21 (32.3%) etanercept and 20 (30.8%) adalimumab. Pre-treatment, 46 (70.8%) were in employment (1 was a student); 38 (58.5%) were working full-time and 8 (12.3%) part-time; 19 (29.2%) were not working. On treatment, 50 (76.9%) patients were working, 44 (67.7%) full-time and 6 (9.2%) part-time. Two individuals who worked part-time pre-treatment had returned to work full-time. Thus, on treatment, 4 of the 19 patients who were previously unable to work returned to employment, and 2 others increased their work from part-time to full-time. Patients rated the effect of AS on work capacity as 7.05/10 pre-treatment and 2.92/10 post-treatment. Those who were working lost, on average, 15 days from work due to sick leave in the 12 months pre-treatment and 0.91 days in the first 12 months on treatment. CONCLUSIONS: Treatment of active AS with TNF blockade appears to be associated with improved capacity for work.

Item Type: Article
Uncontrolled Keywords: adalimumab,adult,therapeutic use,antibodies, monoclonal, humanized,therapeutic use,drug evaluation,employment,etanercept,female,humans,therapeutic use,infliximab,male,middle aged,motor activity,therapeutic use,severity of illness index,statistics & numerical data,drug therapy,treatment outcome,antagonists & inhibitors,work capacity evaluation
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: LivePure Connector
Date Deposited: 26 Aug 2020 00:02
Last Modified: 22 Oct 2022 06:40
DOI: 10.1093/rheumatology/ken010

Actions (login required)

View Item View Item